tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2015 May 6:1-3. [Epub ahead of print]
[h=1]Are we entering a new age for human vaccine adjuvants?[/h] O'Hagan DT[SUP]1[/SUP], Fox CB.
[h=3]Author information[/h]
[h=3]Abstract[/h] Major advances in adjuvant development, for human vaccines have been reported recently for a range of indications, including malaria, influenza and varicella zoster virus. Furthermore, there is an increased understanding of adjuvant mechanisms of action and a greater emphasis on the importance of formulation and characterization. This progress may signify a new golden age of vaccine adjuvant discovery and development.
[h=4]KEYWORDS:[/h] MF59; MPL; QS21; formulation; vaccine adjuvant
PMID: 25947042 [PubMed - as supplied by publisher]
[h=1]Are we entering a new age for human vaccine adjuvants?[/h] O'Hagan DT[SUP]1[/SUP], Fox CB.
[h=3]Author information[/h]
[h=3]Abstract[/h] Major advances in adjuvant development, for human vaccines have been reported recently for a range of indications, including malaria, influenza and varicella zoster virus. Furthermore, there is an increased understanding of adjuvant mechanisms of action and a greater emphasis on the importance of formulation and characterization. This progress may signify a new golden age of vaccine adjuvant discovery and development.
[h=4]KEYWORDS:[/h] MF59; MPL; QS21; formulation; vaccine adjuvant
PMID: 25947042 [PubMed - as supplied by publisher]